Pfizer says its vaccine continues to be effective against COVID-19 up to six months later.
Pfizer and its German partner, BioNTech, announced updated results Thursday from their ongoing late-stage study of more than 44,000 volunteers.
The companies said the vaccine was 91% effective against symptomatic disease and was even more protective in preventing severe disease. Of 927 confirmed COVID-19 cases detected through March 13, 77 were among people who received the vaccine and 850 were among people who got dummy shots.
There were no serious safety concerns and the vaccine also appeared to work against a variant first detected in South Africa, the companies said.
The U.K. and U.S. gave the emergency green light to roll out Pfizer’s vaccine late last year followed by many other countries. The vaccine is authorized for ages 16 and up.
This week, the companies said the vaccine is safe and strongly protective in kids as young as 12, based on a study of 2,260 U.S. volunteers.
Veetahl Eilat-Raichel, Founder and CEO of Sorbet, shares how employees can harness the value of their time off – and how companies can use PTO to employees’ benefit.
Brooke May, Managing Partner at Evans May Wealth, weighs in on how the market is expected to perform through the rest of 2024, plus why she’s still bullish on tech but cautious when it comes to financials.
Pete Nicoletti, Global CISO at Check Point, explains why it’s so difficult to legislate against A.I. disinformation and why it’s a concern going into the 2024 election.
Michelle Freyre, Clinique Global Brand President, discusses the company's latest ventures and why skin advice should always come from a trusted source.
Jason Tartick, small business expert and TurboTax Live Partner (who you may recognize from 'The Bachelorette'), shares his tips for making sure your taxes are flawless this year.
Christine Short, Head of Research, Global Corporate Events at Wall Street Horizon, a TMX Company, breaks down the biggest takeaways from companies’ quarterly results.
